🇯🇵·13h agoIndustry
Astellas Amends Settlement and License Agreement with MSN regarding Myrbetriq®
Publisher
A
Astellas Pharma
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on newsroom.astellas.com
Leave the platform to read the original full article on the publisher site.
Source: Astellas Pharma
Scope: Industry
Related coverage
More related coverage
Bristol-Myers Squibb News·5h ago
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
Merck & Co. (MSD) News·5h ago
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Chugai Pharmaceutical News·8h ago
2026年12月期第1四半期連結決算
Chugai Pharmaceutical·8h ago